Jefferies Reiterates a Buy Rating on CVS Health (CVS) With a PT of $80

CVS Health Corporation (NYSE:CVS) is one of the top most undervalued low volatility stocks to buy now. In a report released on August 19, Brian Tanquilut from Jefferies reiterated a Buy rating on CVS Health Corporation (NYSE:CVS), setting a price target of $80.00.

In a report released on August 18, UBS also upgraded the stock to a Buy with a $79.00 price target.

CVS Health Corporation (NYSE:CVS) reported its fiscal Q2 2025 results on July 31, with total revenues for the quarter rising to $98.9 billion, up 8.4% compared to the prior year.

GAAP diluted EPS reached $0.80, while adjusted EPS was $1.81. The company also generated $6.5 billion in year-to-date cash flow from operations.

The stock’s median price target of $71.93 implies an upside of 11.91% from current levels.

CVS Health Corporation (NYSE:CVS) is a health solutions company that operates in four segments: healthcare benefits, health services, pharmacy & consumer wellness, and corporate/other. Apart from being a prominent pharmacy chain, the company is one of the largest health insurers in the United States through its Aetna subsidiary’s operations.

While we acknowledge the potential of CVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.